Distinct Expression Patterns of Two Tumor Necrosis Factor Superfamily Member 15 Gene Isoforms in Human Colon Cancer.
Aged
Biomarkers, Tumor
/ genetics
Case-Control Studies
Colonic Neoplasms
/ genetics
Disease Progression
Female
Gene Expression Regulation, Neoplastic
Genetic Predisposition to Disease
Humans
Male
Microsatellite Instability
Middle Aged
Phenotype
Polymorphism, Single Nucleotide
RNA, Messenger
/ genetics
Tumor Necrosis Factor Ligand Superfamily Member 15
/ genetics
Advanced gastric cancer
Colon cancer
TL1A
TNFSF15
VEGI-192
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
04
08
2018
accepted:
29
01
2019
pubmed:
23
2
2019
medline:
24
12
2019
entrez:
22
2
2019
Statut:
ppublish
Résumé
Tumor necrosis factor superfamily member 15 (TNFSF15) gene is involved in development of several cancers. It encodes two proteins: tumor necrosis factor ligand-related molecule 1A (TL1A) and vascular endothelial growth inhibitor 192 (VEGI-192). The main receptor for TL1A is death receptor 3 (DR3). We investigated expression of TL1A, VEGI-192, and DR3 transcripts in different stages of colon cancer and compared them with survival of patients. We also aimed to reveal possible effects of microsatellite instability (MSI) and selected TNFSF15 single-nucleotide polymorphisms (SNPs) on expression of this gene. Forty-five healthy individuals and 95 colon cancer patients were included in the study. Expression of VEGI-192, TL1A, and DR3 was measured by quantitative PCR. SNP and MSI analyses were performed on DNA isolated from normal or cancer tissue. Expression of VEGI-192 and TL1A was elevated in colon cancer, although the level of VEGI-192 decreased, while the level of TL1A increased with the progression of cancer. Patients with low expression of TL1A and/or high expression of VEGI-192 in tumor-transformed tissue showed longer survival. DR3 expression was decreased in the cancer, but it did not change with the tumor progression. Alleles T of rs6478108 and G of rs6478109 SNPs were associated with elevated expression of the TNFSF15 gene. There was no relation between the MSI status and TNFSF15 expression levels. Expression of the TNFSF15 gene isoforms was associated with the progression of colon cancer. Levels of TL1A and VEGI-192 transcripts can be considered as independent prognostic factors for colon cancer.
Sections du résumé
BACKGROUND
Tumor necrosis factor superfamily member 15 (TNFSF15) gene is involved in development of several cancers. It encodes two proteins: tumor necrosis factor ligand-related molecule 1A (TL1A) and vascular endothelial growth inhibitor 192 (VEGI-192). The main receptor for TL1A is death receptor 3 (DR3).
AIMS
We investigated expression of TL1A, VEGI-192, and DR3 transcripts in different stages of colon cancer and compared them with survival of patients. We also aimed to reveal possible effects of microsatellite instability (MSI) and selected TNFSF15 single-nucleotide polymorphisms (SNPs) on expression of this gene.
METHODS
Forty-five healthy individuals and 95 colon cancer patients were included in the study. Expression of VEGI-192, TL1A, and DR3 was measured by quantitative PCR. SNP and MSI analyses were performed on DNA isolated from normal or cancer tissue.
RESULTS
Expression of VEGI-192 and TL1A was elevated in colon cancer, although the level of VEGI-192 decreased, while the level of TL1A increased with the progression of cancer. Patients with low expression of TL1A and/or high expression of VEGI-192 in tumor-transformed tissue showed longer survival. DR3 expression was decreased in the cancer, but it did not change with the tumor progression. Alleles T of rs6478108 and G of rs6478109 SNPs were associated with elevated expression of the TNFSF15 gene. There was no relation between the MSI status and TNFSF15 expression levels.
CONCLUSIONS
Expression of the TNFSF15 gene isoforms was associated with the progression of colon cancer. Levels of TL1A and VEGI-192 transcripts can be considered as independent prognostic factors for colon cancer.
Identifiants
pubmed: 30788683
doi: 10.1007/s10620-019-05507-8
pii: 10.1007/s10620-019-05507-8
pmc: PMC6584785
doi:
Substances chimiques
Biomarkers, Tumor
0
RNA, Messenger
0
TNFSF15 protein, human
0
Tumor Necrosis Factor Ligand Superfamily Member 15
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1857-1867Références
Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66:683–691.
doi: 10.1136/gutjnl-2015-310912
pubmed: 26818619
Hadjipetrou A, Anyfantakis D, Galanakis CG, Kastanakis M, Kastanakis S. Colorectal cancer, screening and primary care: a mini literature review. World J Gastroenterol. 2017;23:6049–6058.
doi: 10.3748/wjg.v23.i33.6049
pubmed: 28970720
pmcid: 5597496
Migone TS, Zhang J, Luo X, et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity. 2002;16:479–492.
doi: 10.1016/S1074-7613(02)00283-2
pubmed: 11911831
Metheny-Barlow LJ, Li LY. Vascular endothelial growth inhibitor (VEGI), an endogenous negative regulator of angiogenesis. Semin Ophthalmol. 2006;21:49–58.
doi: 10.1080/08820530500511446
pubmed: 16517446
Chew LJ, Pan H, Yu J, et al. A novel secreted splice variant of vascular endothelial cell growth inhibitor. FASEB J. 2002;16:742–744.
doi: 10.1096/fj.01-0757fje
pubmed: 11923219
Richard AC, Ferdinand JR, Meylan F, et al. The TNF-family cytokine TL1A: from lymphocyte costimulator to disease co-conspirator. J Leukoc Biol. 2015;98:333–345.
doi: 10.1189/jlb.3RI0315-095R
pubmed: 26188076
pmcid: 4763597
Slebioda TJ, Bojarska-Junak A, Stanislawowski M, et al. TL1A as a potential local inducer of IL17A expression in colon mucosa of inflammatory bowel disease patients. Scand J Immunol. 2015;82:352–360.
doi: 10.1111/sji.12324
pubmed: 26072972
Slebioda TJ, Kmiec Z. Tumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel disease. Mediators Inflamm. 2014;2014:325129.
doi: 10.1155/2014/325129
pubmed: 25045210
pmcid: 4087264
Zhang N, Sanders AJ, Ye L, Jiang WG. Vascular endothelial growth inhibitor in human cancer (Review). Int J Mol Med. 2009;24:3–8.
pubmed: 19513527
Tian F, Liang PH, Li LY. Inhibition of endothelial progenitor cell differentiation by VEGI. Blood. 2009;113:5352–5360.
doi: 10.1182/blood-2008-08-173773
pubmed: 19329781
pmcid: 2686197
Hou W, Medynski D, Wu S, Lin X, Li LY. VEGI-192, a new isoform of TNFSF15, specifically eliminates tumor vascular endothelial cells and suppresses tumor growth. Clin Cancer Res. 2005;11:5595–5602.
doi: 10.1158/1078-0432.CCR-05-0384
pubmed: 16061878
Zhang N, Wu P, Wu L, et al. The differential expression of vascular endothelial growth inhibitor isoforms, VEGI251, VEGI174 and VEGI192 in human clear-cell renal cell carcinoma. Cancer Genomics Proteomics. 2013;10:47–53.
pubmed: 23382586
Zhao Q, Liu T, Hong B, et al. Vascular Endothelial Growth Inhibitor, a Cytokine of the Tumor Necrosis Factor Family, is Associated With Epithelial-Mesenchymal Transition in Renal Cell Carcinoma. Applied immunohistochemistry & molecular morphology: AIMM; 2017.
doi: 10.1097/PAI.0000000000000517
Jia W, Sander AJ, Jia G, et al. Vascular endothelial growth inhibitor (VEGI) is an independent indicator for invasion in human pituitary adenomas. Anticancer Res. 2013;33:3815–3822.
pubmed: 24023314
Slebioda TJ, Rowley TF, Ferdinand JR, et al. Triggering of TNFRSF25 promotes CD8(+) T-cell responses and anti-tumor immunity. Eur J Immunol. 2011;41:2606–2611.
doi: 10.1002/eji.201141477
pubmed: 21688261
Zhang Z, Yu D, Lu J, et al. Functional genetic variants of TNFSF15 and their association with gastric adenocarcinoma: a case–control study. PLoS ONE. 2014;9:e108321.
doi: 10.1371/journal.pone.0108321
pubmed: 25251497
pmcid: 4176965
Sun Y, Irwanto A, Toyo-Oka L, et al. Fine-mapping analysis revealed complex pleiotropic effect and tissue-specific regulatory mechanism of TNFSF15 in primary biliary cholangitis. Crohn’s disease and leprosy. Sci Rep. 2016;6:31429.
doi: 10.1038/srep31429
pubmed: 27507062
pmcid: 4979016
Ye BD, Choi H, Hong M, et al. Identification of ten additional susceptibility loci for ulcerative colitis through immunochip analysis in Koreans. Inflamm Bowel Dis. 2016;22:13–19.
doi: 10.1097/MIB.0000000000000584
pubmed: 26398853
Kepiro L, Szell M, Kovacs L, et al. Genetic risk and protective factors of TNFSF15 gene variants detected using single nucleotide polymorphisms in Hungarians with psoriasis and psoriatic arthritis. Hum Immunol. 2014;75:159–162.
doi: 10.1016/j.humimm.2013.11.006
pubmed: 24269700
Simon K. Colorectal cancer development and advances in screening. Clin Interv Aging. 2016;11:967–976.
doi: 10.2147/CIA.S109285
pubmed: 27486317
pmcid: 4958365
Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138:2073–2087.e3.
doi: 10.1053/j.gastro.2009.12.064
pubmed: 20420947
van de Velde CJ, Boelens PG, Borras JM, et al. EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. Eur J Cancer. 2014;50:1.e1–1.e34.
doi: 10.1016/j.ejca.2013.06.048
Park MH, Song MJ, Cho MC, et al. Interleukin-32 enhances cytotoxic effect of natural killer cells to cancer cells via activation of death receptor 3. Immunology. 2012;135:63–72.
doi: 10.1111/j.1365-2567.2011.03513.x
pubmed: 22043900
pmcid: 3246653
Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Can Res. 1998;58:5248–5257.
Wierzbicki PM, Adrych K, Kartanowicz D, et al. Underexpression of LATS1 TSG in colorectal cancer is associated with promoter hypermethylation. World J Gastroenterol. 2013;19:4363–4373.
doi: 10.3748/wjg.v19.i27.4363
pubmed: 23885148
pmcid: 3718905
Janavicius R, Matiukaite D, Jakubauskas A, Griskevicius L. Microsatellite instability detection by high-resolution melting analysis. Clin Chem. 2010;56:1750–1757.
doi: 10.1373/clinchem.2010.150680
pubmed: 20852132
Weidner N. Angiogenesis as a predictor of clinical outcome in cancer patients. Hum Pathol. 2000;31:403–405.
doi: 10.1053/hp.2000.6724
pubmed: 10821484
Bittner S, Knoll G, Ehrenschwender M. Death receptor 3 signaling enhances proliferation of human regulatory T cells. FEBS Lett. 2017;591:1187–1195.
doi: 10.1002/1873-3468.12632
pubmed: 28337757
Karin M. NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol. 2009;1:a000141.
doi: 10.1101/cshperspect.a000141
pubmed: 20066113
pmcid: 2773649
Maisey N. Antitumor necrosis factor (TNF-a) antibodies in the treatment of renal cell cancer. Cancer Invest. 2007;25:589–593.
doi: 10.1080/07357900701359700
pubmed: 17852116
Harrison ML, Obermueller E, Maisey NR, et al. Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol. 2007;25:4542–4549.
doi: 10.1200/JCO.2007.11.2136
pubmed: 17925549
Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev. 2006;25:409–416.
doi: 10.1007/s10555-006-9005-3
pubmed: 16951987
Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431:461–466.
doi: 10.1038/nature02924
pubmed: 15329734
Moorchung N, Kunwar S, Ahmed KW. An evaluation of nuclear factor kappa B expression in colorectal carcinoma: an analysis of 50 cases. J Cancer Res Ther. 2014;10:631–635.
pubmed: 25313751
Niu W, Wu Z, Wang J, et al. Tumor necrosis factor ligand-related molecule 1A regulates the occurrence of colitis-associated colorectal cancer. Dig Dis Sci. 2018;63:2341–2350. https://doi.org/10.1007/s10620-018-5126-0 .
doi: 10.1007/s10620-018-5126-0
pubmed: 29796912
Gout S, Morin C, Houle F, Huot J. Death receptor-3, a new E-Selectin counter-receptor that confers migration and survival advantages to colon carcinoma cells by triggering p38 and ERK MAPK activation. Can Res. 2006;66:9117–9124.
doi: 10.1158/0008-5472.CAN-05-4605
Zhang L, Zhang Y, Zhang L, Yang X, Lv Z. Lupeol, a dietary triterpene, inhibited growth, and induced apoptosis through down-regulation of DR3 in SMMC7721 cells. Cancer Invest. 2009;27:163–170.
doi: 10.1080/07357900802210745
pubmed: 19235588
Ge Z, Sanders AJ, Ye L, Mansel RE, Jiang WG. Expression of death receptor-3 in human breast cancer and its functional effects on breast cancer cells in vitro. Oncol Rep. 2013;29:1356–1364.
doi: 10.3892/or.2013.2259
pubmed: 23443464
Baskaran K, Pugazhendhi S, Ramakrishna BS. Protective association of tumor necrosis factor superfamily 15 (TNFSF15) polymorphic haplotype with Ulcerative Colitis and Crohn’s disease in an Indian population. PLoS ONE. 2014;9:e114665.
doi: 10.1371/journal.pone.0114665
pubmed: 25501099
pmcid: 4264777
Connelly TM, Choi CS, Berg AS, et al. Diverticulitis and Crohn’s disease have distinct but overlapping tumor necrosis superfamily 15 haplotypes. J Surg Res. 2017;214:262–269.
doi: 10.1016/j.jss.2017.02.030
pubmed: 28624054
Hedl M, Abraham C. A TNFSF15 disease-risk polymorphism increases pattern-recognition receptor-induced signaling through caspase-8-induced IL-1. Proc Natl Acad Sci USA. 2014;111:13451–13456.
doi: 10.1073/pnas.1404178111
pubmed: 25197060
pmcid: 4169936
Bamias G, Martin C 3rd, Marini M, et al. Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J Immunol. 2003;171:4868–4874.
doi: 10.4049/jimmunol.171.9.4868
pubmed: 14568967
Zhang E, Zhu X, Han S, et al. Increased expression of TNF ligand-related molecule 1A and death receptor 3 in bladder tissues of patients with painful bladder syndrome/interstitial cystitis. Exp Ther Med. 2013;5:282–286.
doi: 10.3892/etm.2012.778
pubmed: 23251284